Vicore Pharma Holding AB reported unaudited financial results for the second quarter ended June 30, 2026. The company completed patient recruitment in its Phase 2b ASPIRE trial evaluating buloxibutid for idiopathic pulmonary fibrosis (IPF), enrolling over 360 patients across 14 countries ahead of schedule, with topline results expected in mid-2027. Financially, net revenues were SEK 2.2 million and operating loss was SEK 150.1 million for the quarter. Cash and short-term investments stood at SEK 905.6 million (USD 93.0 million) as of June 30, providing a runway into late 2028. Post-period, Vicore commenced dual listing on Nasdaq Capital Market under ticker VCRE in July and appointed Rob Slack as Chief Scientific Officer. Vicore Pharma is a clinical-stage biopharmaceutical company developing angiotensin II type 2 receptor agonists for respiratory and fibrotic diseases.